GeneDx Holdings Corp. (WGS) Key Metrics
WGS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.90B
- Enterprise value
- $2.58B
- P/E (TTM)
- —
- Forward P/E
- 63.3
- PEG ratio
- —
- Price / sales
- 4.2 10-yr median 3.6
- Price / book
- 10.4 10-yr median 4.4
- EV / EBITDA
- 161.2
- Dividend yield
- —
- Beta
- 1.97
WGS key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsWGS valuation Price multiples at each fiscal year-end price.
WGS returns How much profit the business earns on the capital it uses.
WGS per-share figures Results divided by the shares outstanding at year-end.
WGS financial health Debt, liquidity and how easily interest is covered.
WGS efficiency & capital use Working capital cycle and where the cash goes.
WGS valuation history
WGS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
WGS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
WGS price vs earnings per share
WGS key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $3.50B | $2.07B | $66.9M | $89.2M | — | — | — |
| Enterprise value | $3.48B | $2.04B | $56.5M | $28.9M | — | — | — |
| Price / sales | 8.2 | 6.8 | 0.3 | 0.4 | — | — | — |
| Price / book | 11.3 | 8.4 | 0.3 | 0.4 | — | — | — |
| Price / free cash flow | 245.2 | — | — | — | — | — | — |
| Price / operating cash flow | 105.1 | — | — | — | — | — | — |
| EV / sales | 8.1 | 6.7 | 0.3 | 0.1 | — | — | — |
| EV / EBITDA | 524.9 | — | — | — | — | — | — |
| EV / free cash flow | 243.9 | — | — | — | — | — | — |
| Earnings yield | −0.6% | −2.5% | −262.9% | −615.6% | — | — | — |
| Free cash flow yield | 0.4% | −1.6% | −278.0% | −373.9% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | — | — |
| Share price at fiscal year-end | $130.06 | $76.86 | $2.75 | $8.71 | $147.18 | $364.32 | — |
| Per share | |||||||
| Revenue per share | $15.90 | $11.36 | $8.33 | $22.93 | — | — | — |
| Earnings per share | −$0.78 | −$1.94 | −$7.23 | −$53.63 | — | — | — |
| Operating cash flow per share | $1.24 | −$1.06 | −$7.41 | −$31.18 | — | — | — |
| Free cash flow per share | $0.53 | −$1.26 | −$7.64 | −$32.58 | — | — | — |
| Cash per share | $6.37 | $5.25 | $5.35 | $13.42 | — | — | — |
| Book value per share | $11.46 | $9.12 | $9.38 | $24.78 | — | — | — |
| Tangible book value per share | $4.69 | $3.22 | $2.28 | $6.55 | — | — | — |
| Capex per share | $0.71 | $0.20 | $0.23 | $1.40 | — | — | — |
| Debt per share | $5.65 | $4.32 | $4.93 | $7.53 | — | — | — |
| Shares outstanding | 26.9M | 26.9M | 24.3M | 10.2M | — | — | — |
| Change in shares outstanding | 0.0% | +10.6% | +137.5% | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −7.6% | −22.1% | −73.0% | −171.1% | −125.0% | — | — |
| Return on invested capital (ROIC) | −3.7% | −8.4% | −69.4% | −493.4% | — | — | — |
| Return on assets (ROA) | −4.2% | −12.5% | −36.5% | −99.9% | −60.9% | −95.9% | — |
| Return on tangible assets | −5.4% | −20.0% | −71.4% | −153.1% | −44.3% | −95.9% | — |
| Free cash flow margin | 3.3% | −11.1% | −91.8% | −142.1% | −99.5% | −69.8% | −17.4% |
| Financial health | |||||||
| Total debt | $151.9M | $116.2M | $119.8M | $77.1M | $32.8M | $43.3M | — |
| Cash & short-term investments | $171.3M | $141.2M | $130.1M | $137.4M | $400.6M | $108.1M | — |
| Net debt | −$19.3M | −$25.0M | −$10.4M | −$60.3M | −$367.7M | −$64.9M | — |
| Debt / equity | 0.49 | 0.47 | 0.53 | 0.30 | 0.08 | 9.86 | — |
| Debt / assets | 0.27 | 0.28 | 0.29 | 0.14 | 0.06 | 0.17 | — |
| Net debt / EBITDA | −2.92 | — | — | — | — | — | — |
| Current ratio | 2.46 | 3.61 | 3.10 | 1.47 | 4.77 | 2.37 | 4.08 |
| Quick ratio | 2.34 | 3.42 | 2.95 | 1.38 | 4.44 | 2.03 | 3.68 |
| Interest coverage | -4.6 | -7.7 | — | -208.2 | -157.4 | -97.8 | -38.8 |
| Working capital | $159.4M | $143.2M | $123.5M | $68.3M | $382.3M | $100.7M | $123.6M |
| Invested capital | $288.8M | $220.2M | $217.6M | $193.4M | $20.4M | −$60.5M | — |
| Tangible asset value | $126.2M | $86.6M | $55.4M | $67.1M | $388.1M | $4.4M | — |
| Net current asset value | $6.3M | $23.8M | −$8.4M | −$78.9M | $317.6M | −$73.1M | — |
| Graham net-net per share | −$1.04 | $0.02 | −$1.30 | −$11.22 | — | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | $0 | — | — | — |
| Capex / revenue | 4.4% | 1.8% | 2.8% | 6.1% | 9.8% | 17.8% | 7.9% |
| Capex / operating cash flow | 57.1% | — | — | — | — | — | — |
| Capex / depreciation | 0.75 | 0.25 | 0.17 | 0.24 | 0.95 | 2.72 | 2.41 |
| Stock-based compensation / revenue | 7.5% | 3.0% | −0.2% | 17.9% | 103.4% | 67.0% | 2.8% |
| R&D / revenue | 16.8% | 15.0% | 28.8% | 36.7% | 49.6% | 40.5% | 17.8% |
| SG&A / revenue | 56.0% | 55.2% | 96.1% | 144.1% | 150.2% | 91.4% | 35.1% |
| Efficiency | |||||||
| Days sales outstanding | 47.8 | 42.1 | 68.6 | 54.4 | 50.7 | 54.9 | 40.3 |
| Days of inventory on hand | 34.7 | 31.9 | 36.4 | 32.9 | 46.6 | 42.6 | 51.4 |
| Days payables outstanding | 14.7 | 29.9 | 91.2 | 63.3 | 57.0 | 46.0 | 56.3 |
| Cash conversion cycle (days) | 67.8 | 44.1 | 13.8 | 23.9 | 40.3 | 51.5 | 35.5 |
| Receivables turnover | 7.63 | 8.67 | 5.32 | 6.71 | 7.21 | 6.65 | 9.07 |
| Payables turnover | 24.84 | 12.21 | 4.00 | 5.76 | 6.41 | 7.93 | 6.49 |
| Inventory turnover | 10.52 | 11.43 | 10.03 | 11.10 | 7.83 | 8.56 | 7.09 |
| Asset turnover | 0.86 | 0.73 | 0.42 | 0.43 | 0.53 | 0.71 | — |
| Average receivables | $56.0M | $35.2M | $38.1M | $35.0M | $29.4M | $27.0M | $21.6M |
| Average payables | $5.2M | $9.1M | $28.1M | $45.4M | $35.7M | $22.1M | $17.5M |
| Average inventory | $12.3M | $9.7M | $11.2M | $23.6M | $29.2M | $20.5M | $16.0M |
| Intangibles / total assets | 31.9% | 37.8% | 41.2% | 34.2% | 0.0% | 0.0% | — |
Computed from WGS's annual financial statements (latest annual report filed February 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
WGS valuation and financial ratios
GeneDx earned a return on equity of −7.6% and a return on invested capital of −3.7% in fiscal 2025. It ended the year with $151.9 million of debt and $171.3 million in cash and short-term investments, a net cash position of $19.3 million.
See the WGS income statement, the WGS chart for price history, or the WGS stock overview for the latest quote and news.
WGS key metrics FAQ
What is GeneDx's EV/EBITDA?
GeneDx's enterprise value was 524.9 times EBITDA at the end of fiscal 2025 (enterprise value $3.5 billion, EBITDA $6.6 million); the current EV/EBITDA is 161.2.
What is GeneDx's return on equity?
GeneDx's return on equity (ROE) was −7.6% in fiscal 2025: net income of -$21.0 million on average shareholders' equity of $276.7 million.
What is GeneDx's ROIC?
GeneDx's return on invested capital was −3.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does GeneDx have?
GeneDx had total debt of $151.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.49 and more cash than debt.
What is GeneDx's free cash flow yield?
GeneDx generated $14.3 million of free cash flow in fiscal 2025, a free cash flow yield of 0.4% on its market value at year-end ($3.5 billion).
What is GeneDx's current ratio?
GeneDx's current ratio was 2.46 at the end of fiscal 2025: current assets were 2.46 times current liabilities.